Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma

Molecular Carcinogenesis

Volumn 52, Issue 5, 2013, Pages 377-386

  Eslin, Don ^a,b   Sankpal, Umesh T ^a   Lee, Chris ^a   Sutphin, Robert M ^a,b   Maliakal, Pius ^a,c   Currier, Erika ^d   Sholler, Giselle ^e   Khan, Moeez ^a   Basha, Riyaz ^a,c,f  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

NSAID; Pediatric tumors; Sp1; Survivin; Transcription factors

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; SURVIVIN; TOLFENAMIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LYSATE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOSIS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEUROBLASTOMA; ORTHO-AMINOBENZOATES; POLY(ADP-RIBOSE) POLYMERASES; SP1 TRANSCRIPTION FACTOR;

EID: 84876143720     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21866     Document Type: Article

References (57)

1. Bowen KA, Chung DH. Recent advances in neuroblastoma. Curr Opin Pediatr 2009; 21: 350-356.
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211.
3. Schwab M, Evans A. Neuroblastoma-Developmental and molecular biology meet therapy design. Cancer Lett 2003; 197: 1.
4. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol 2003; 4: 472-480.
5. van Ginkel PR, Sareen D, Subramanian L, et al. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 2007; 13: 5162-5169.
6. Carosio R, Zuccari G, Orienti I, Mangraviti S, Montaldo PG. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer 2007; 6: 55.
7. Ebb DH, Green DM, Shamberger RC, Tarbell NJ. Solid tumors of childhood. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology, 6th edition. Philadelphia: Williams andWilkins; 2001. p. 2169.
8. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 2006; 98: 855-8868.
9. Basha R, Baker CH, Sankpal UT, et al. Therapeutic applications of NSAIDS in cancer: Special emphasis on tolfenamic acid. Front Biosci (Schol Ed) 2011; 3: 797-805.
10. Chang WC, Chen BK. Transcription factor Sp1 functions as an anchor protein in gene transcription of human 12(S)-lipoxygenase. Biochem Biophys Res Commun 2005; 338: 117-121.
11. Lu S, Archer MC. Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells. Int J Cancer 2009; 2: 416-425.
12. Basha R, Ingersoll SB, Sankpal UT, et al. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011; 122: 163-170.
13. Konduri S, Colon J, Baker CH, et al. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 2009; 8: 533-542.
14. Maliakal P, Abdelrahim M, Sankpal UT, et al. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 2011; [Epub ahead of print].
15. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002; 62: 1802-1808.
16. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-591.
17. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-854.
18. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
19. Tang XX, Zhao H, Kung B, et al. The MYCN enigma: Significance of MYCN expression in neuroblastoma. Cancer Res 2006; 66: 2826-2833.
20. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy. Semin Oncol 2004; 31: 2-11.
21. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-5044.
22. Tarnawski AS, Jones MK. Inhibition of angiogenesis by NSAIDs: Molecular mechanisms and clinical implications. J Mol Med 2003; 81: 627-636.
23. Colon J, Basha MR, Madero-Visbal R, et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011; 29: 41-51.
24. Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10: 4109-4117.
25. Adwan LI, Basha R, Abdelrahim M, Subaiea GM, Zawia NH. Tolfenamic acid interrupts the de novo synthesis of the beta-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway. Curr Alzheimer Res 2011; 8: 385-392.
26. Subaiea GM, Alansi BH, Serra DA, Alwan M, Zawia NH. The ability of tolfenamic acid to penetrate the brain: A model for testing the brain disposition of candidate Alzheimer's drugs using multiple platforms. Curr Alzheimer Res 2011; 8: 860-867.
27. Deveraux QL, Reed JC. IAP family proteins-Suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
28. Doolittle H, Morel A, Talbot D. Survivin-directed anticancer therapies. A review of pre-clinical data and early-phase clinical trials. Eur Oncol 2010; 6: 10-14.
29. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005.
30. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-615.
31. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351: 882-883.
32. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-623.
33. Obexer P, Hagenbuchner J, Unterkircher T, et al. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. Mol Biol Cell 2009; 20: 2041-2048.
34. Chen Y, Wang X, Li W, et al. Sp1 upregulates survivin expression in adenocarcinoma of lung cell line A549. Anat Rec (Hoboken) 2011; 294: 774-780.
35. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED. Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc) 2008; 73: 1183-1191.
36. Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G. Sp1 and Sp3 regulate basal transcription of the survivin gene. Biochem Biophys Res Commun 2007; 356: 286-292.
37. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS. Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 2008; 7: 569-576.
38. Saulnier Sholler GL, Brard L, Straub JA, et al. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J Pediatr Hematol Oncol 2009; 31: 187-193.
39. Matthay KK. Neuroblastoma: A clinical challenge and biologic puzzle. CA Cancer J Clin 1995; 45: 179-192.
40. Abdelrahim M, Safe S, Baker C, Abudayyeh A. RNAi and cancer: Implications and applications. J RNAi Gene Silencing 2006; 2: 136-145.
41. Papineni S, Chintharlapalli S, Abdelrahim M, et al. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009; 30: 1193-1201.
42. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-1139.
43. Li Y, Xie M, Yang J, et al. The expression of antiapoptotic protein survivin is transcriptionally upregulated by DEC1 primarily through multiple sp1 binding sites in the proximal promoter. Oncogene 2006; 25: 3296-3306.
44. Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ. Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ 2007; 14: 318-326.
45. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 635-640.
46. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, Shafit-Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 2001; 79: 426-436.
47. Zhang XD, Gillespie SK, Hersey P. Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 2004; 3: 187-197.
48. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005; 5: 366-373.
49. Craig C, Wersto R, Kim M, et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997; 14: 2283-2289.
50. Lee YM, Lim do Y, Cho HJ, et al. Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity. Cancer Lett 2009; 285: 166-173.
51. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: Implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5: 127-156.
52. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP. Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 2010; 9: 689-699.
53. Hendel L, Larsen E, Bonnevie O. A comparative study of the influence of tolfenamic acid (Clotam) and diclofenac sodium (Voltaren) on the gastrointestinal mucosa in patients with a history of NSAID-related dyspeptic symptoms. Pharmacol Toxicol 1994; 75: 49-50.
54. Khalifah RG, Hignite CE, Pentikainen PJ, Penttila A, Neuvonen PJ. Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates. Eur J Drug Metab Pharmacokinet 1982; 7: 269-276.
55. Vale JA, Meredith TJ. Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management. Med Toxicol 1986; 1: 12-31.
56. Eskerod O. Gastrointestinal tolerance studies on tolfenamic acid in humans and animals. Pharmacol Toxicol 1994; 75: 44-48.
57. Pentikainen PJ, Tokola O, Alhava E, Penttila A. Pharmacokinetics of tolfenamic acid: Disposition in bile, blood and urine after intravenous administration to man. Eur J Clin Pharmacol 1984; 27: 349-354.